Market Spotlight: Hidradenitis Suppurativa

  • ID: 4533485
  • Report
  • 24 pages
  • Datamonitor Healthcare
1 of 3
This Market Spotlight report covers the Hidradenitis Suppurativa market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, epidemiology, and drug-specific revenue forecasts.

Key Takeaways
  • All approved drugs for hidradenitis suppurativa target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, except for Humira, which is both an intravenous and a subcutaneous formulation.
  • Pipeline therapies for hidradenitis suppurativa include two Phase II drugs and one drug in BLA phase. All the pipeline therapies are administered via the subcutaneous or intravenous routes.
  • Therapies in development for hidradenitis suppurativa target tumor necrosis factor-alpha and interleukin-17. All of the pipeline therapies are administered via the subcutaneous or intravenous routes.
  • The Netherlands has a lead in the number of hidradenitis suppurativa clinical trials globally.
  • Abott has the highest number of completed clinical trials for hidradenitis suppurativa, with two completed trials.
  • AbbVie is the only sponsor which has carried out a Phase III trial in hidradenitis suppurativa.
Note: Product cover images may vary from those shown
2 of 3
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
Hidradenitis Suppurativa Subtypes

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS IN THE US

KEY REGULATORY EVENTS
BI’s Cyltezo Becomes 15th EU Biosimilar This Year, Adds To Pressure On Humira
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Samsung Bioepis Builds Its Biosimilars Name In Europe
EU CHMP OKs Imraldi, Samsung Bioepis’ Biosimilar Of AbbVie’s Humira
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

BIBLIOGRAPHY
Prescription Information:

APPENDIX

List of Figures
Figure 1: Overview of pipeline drugs for hidradenitis suppurativa in the US
Figure 2: Pipeline drugs for hidradenitis suppurativa, by company
Figure 3: Pipeline drugs for hidradenitis suppurativa, by drug type
Figure 4: Pipeline drugs for hidradenitis suppurativa, by classifications
Figure 5: Parent patents in hidradenitis suppurativa
Figure 6: Clinical trials in hidradenitis suppurativa
Figure 7: Top 10 drugs for clinical trials in hidradenitis suppurativa
Figure 8: Top 10 companies for clinical trials in hidradenitis suppurativa
Figure 9: Trial locations in hidradenitis suppurativa
Figure 10: Hidradenitis suppurativa trials status
Figure 11: Hidradenitis suppurativa trials sponsors, by phase

List of Tables
Table 1: Marketed drugs for hidradenitis suppurativa
Table 2: Approvals by country for hidradenitis suppurativa
Table 3: Pipeline drugs for hidradenitis suppurativa in the US
Table 4: Historical global sales, by drug ($m), 2012-16
Table 5: Forecasted global sales, by drug ($m), 2017-22
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll